COVID-19 Autoimmune

Updated January 8, 2022

18 NOV 2020: Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19 (Science)
“These findings suggest that half of patients hospitalized with COVID-19 become at least transiently positive for aPL antibodies and that these autoantibodies are potentially pathogenic.”

19 JAN 2021: Reaction of Human Monoclonal Antibodies to SARS-CoV-2 Proteins With Tissue Antigens: Implications for Autoimmune Diseases (Frontiers in Immunology)
“our results can establish the potential risk for autoimmunity and multi-system disorders with COVID-19 that may come from cross-reactivity between our own human tissues and this dreaded virus”

24 Jun 2021: Autoantibodies stabilize neutrophil extracellular traps in COVID-19 (JCI Insight)
Press Release:

1 JUL 2021: Multisystem Inflammatory Syndrome after SARS-CoV-2 Infection and COVID-19 Vaccination (CDC)

7 JUL 2021: How antibodies may cause rare blood clots after some COVID-19 vaccines (ScienceNews)

27 JUL 2021: Relaxed peripheral tolerance drives broad de novo autoreactivity in severe COVID-19 (medRxiv preprint)
“this study reveals the origins, breadth, and resolution of acute-phase autoreactivity in severe COVID-19, with significant implications in both early interventions and potential treatment of patients with post-COVID sequelae

29 JUL 2021: Multisystem inflammatory syndrome in an adult following the SARS-CoV-2 vaccine (MIS-V)  (BMJ Case Reports)

11 AUG 2021: Researchers find important clue to rare inflammatory disease in children following COVID-19 infection (MedicalXpress press release)

14 SEP 2021: New-onset IgG autoantibodies in hospitalized patients with COVID-19 (Nature)

7 OCT 2021: Association of Receipt of the Ad26.COV2.S COVID-19 Vaccine With Presumptive Guillain-Barré Syndrome (JAMA)

25 OCT 2021: Anti–SARS-CoV-2 and Autoantibody Profiles in the Cerebrospinal Fluid of 3 Teenaged Patients With COVID-19 and Subacute Neuropsychiatric Symptoms (JAMA)
“A subset of pediatric patients with COVID-19 and subacute neuropsychiatric symptoms have intrathecal antineural autoantibodies, suggesting central nervous system autoimmunity in pediatric patients with COVID-19 and recent neuropsychiatric symptoms.”

24 NOV 2021: A Possible Role for Anti-idiotype Antibodies in SARS-CoV-2 Infection and Vaccination (NEJM)

1 DEC 2021: ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome (Science)

5 DEC 2021: Brain Injury in COVID-19 is Associated with Autoinflammation and Autoimmunity (medRxiv preprint)

5 DEC 2021: Guillain-Barré Syndrome after COVID-19 Vaccination in the Vaccine Safety Datalink (medRxiv preprint)
“In this interim analysis of surveillance data of COVID-19 vaccines, the incidence of GBS was elevated after Ad.26.COV2.S. Surveillance is ongoing.”

20 DEC 2021: Multisystem Inflammatory Syndrome in Children by COVID-19 Vaccination Status of Adolescents in France (JAMA Research Letter)
“These results suggest that COVID-19 mRNA vaccination was associated with a lower incidence of MIS-C in adolescents.” 

30 DEC 2021: Paradoxical sex-specific patterns of autoantibody response to SARS-CoV-2 infection (Journal of Translational Med)
“Our results reveal that prior SARS-CoV-2 infection, even in the absence of severe clinical disease, can lead to a broad AAB response that exhibits sex-specific patterns of prevalence and antigen selectivity. Further understanding of the nature of triggered AAB activation among men and women exposed to SARS-CoV-2 will be essential for developing effective interventions against immune-mediated sequelae of COVID-19.”
Press Release:
“These patterns of immune dysregulation could be underlying the different types of persistent symptoms we see in people who go on to develop the condition now referred to as long COVID-19.”

5 JAN 2022: Reported Cases of Multisystem Inflammatory Syndrome in Children (MIS-C) Aged 12–20 Years in the United States Who Received COVID-19 Vaccine, December 2020 through August 2021 (medRxiv preprint)
“In our case series, we describe a small number of persons with MIS-C who had received ≥1 COVID-19 vaccine dose before illness onset. Continued reporting of potential cases and surveillance for MIS-C illnesses after COVID-19 vaccination is warranted.”